An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer
暂无分享,去创建一个
[1] R. Ausman,et al. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast , 1987, Breast Cancer Research and Treatment.
[2] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. Reigner,et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. Ellis,et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Gabra,et al. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. , 1996, British Journal of Cancer.
[6] T. Powles,et al. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. , 1996, British Journal of Cancer.
[7] T. Powles,et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] B. Gusterson,et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] V. Semiglazov,et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] D. Talbot,et al. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Norton,et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.
[12] B. Asselain,et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. , 1994, European journal of cancer.
[13] V. Bramwell,et al. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. , 1992, European journal of cancer.
[14] L. Mauriac,et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] P. Benotti,et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.
[16] J. Lokich,et al. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. , 1984, Annals of internal medicine.